| Company Name: |
Elucigen bio Gold |
| Tel: |
13501719342 13501719342 |
| Email: |
wayne.zheng@elucigenbio.com |
| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- MIK665
-
- $135.00
-
2026-07-14
- CAS:1799631-75-6
- Purity: 95.47%
- Supply Ability: 10g
- MIK665
-
- $135.00
-
2026-07-14
- CAS:1799631-75-6
- Purity: 95.47%
- Supply Ability: 10g
|
| Product Name: | MIK665 | | Synonyms: | MIK665;MIK665,S64315;S64315 (MIK665);(2S)-2-(5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yloxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid;MIK665 (S-64315, MIK-665);Benzenepropanoic acid, α-[[(5S)-5-[3-chloro-2-methyl-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy]-2-[[2-(2-methoxyphenyl)-4-pyrimidinyl]methoxy]-, (αR)-;(5S)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid;S64315(MIK665 ,S-64315) | | CAS: | 1799631-75-6 | | MF: | C47H44ClFN6O6S | | MW: | 875.41 | | EINECS: | | | Product Categories: | | | Mol File: | 1799631-75-6.mol |  |
| | MIK665 Chemical Properties |
| Boiling point | 909.4±65.0 °C(Predicted) | | density | 1.324±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: soluble | | form | A solid | | pka | 2.53±0.11(Predicted) | | color | White to off-white | | InChIKey | PKYIMGFMRFVOMB-UHFFFAOYSA-N | | SMILES | O(C1N=CN=C2SC(C3C=CC(F)=CC=3)=C(C3C=CC(OCCN4CCN(C)CC4)=C(Cl)C=3C)C=12)C(C(=O)O)CC1C=CC=CC=1OCC1C=CN=C(C2C=CC=CC=2OC)N=1 |
| | MIK665 Usage And Synthesis |
| Uses | MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor[1]. MIK665 has an IC50 of 1.81 nM for MCL1[2]. | | IC 50 | Mcl-1: 1.81 nM (IC50) | | References | [1] Mukherjee N, et al. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers (Basel). 2020;12(8):2182. Published 2020 Aug 5. DOI:10.3390/cancers12082182 [2] Zoltán SZLáVIK, et al. New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. WO2016207225A1. |
| | MIK665 Preparation Products And Raw materials |
|